High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer

被引:47
|
作者
Lin, Yang [1 ]
Lv, Feng [1 ]
Liu, Fangfang [1 ]
Guo, Xiaojing [1 ]
Fan, Yu [1 ]
Gu, Feng [1 ]
Gu, Jun [2 ,3 ]
Fu, Li [1 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc Pathol & Res Lab,Natl Clin Res C, Key Lab Breast Canc Prevent & Therapy,Minst Educ, Tianjin 300060, Peoples R China
[2] SUNY Albany, Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA
[3] SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 11期
基金
中国国家自然科学基金;
关键词
Pyruvate kinase M2; breast cancer chemosensitivity; epirubicin; 5-fluorouracil; DRUG-SENSITIVITY TEST; IN-VITRO; PKM2; CULTURE; CHEMOTHERAPY; RESISTANCE; CELLS; INHIBITION; PROGNOSIS; THERAPY;
D O I
10.7150/jca.12719
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pyruvate kinase M2 (PKM2) is the key enzyme in the Warburg effect, and it was recently reported to be involved in the metabolic pathways of chemotherapeutic drugs. However, the role of PKM2 in breast cancer and its influence in the sensitivity to front-line anticancer drugs remains unclear. Methods: In this study, we examined the correlation between the expression of PKM2 and the sensitivity of primary breast cancer cells to anticancer drugs. PKM2 expression was studied by immunohistochemistry using biopsy samples of 296 patients diagnosed with invasive breast carcinoma, and the collagen gel droplet embedded culture-drug sensitivity tests (CD-DST) was conducted to all the patients to detect in vitro chemosensitivity after surgery. Results: We found high PKM2 expression was significantly associated with in vitro chemosensitivity to epirubicin (EPI) (P=0.019) and 5-fluorouracil (5-Fu) (P=0.009) in breast cancer patients. Then we used a small group of neoadjuvant chemotherapy cases to confirm that the higher PKM2 expression, the better pathological response to therapy was obtained in patients treated with EPI-based or EPI plus 5-Fu chemotherapy regimens. Although univariate and multivariate analysis indicated that high PKM2 was a poor independent predictor of progression free survival (PFS) and overall survival (OS) in breast cancer, patients with PKM2 high expression who received EPI-based or EPI plus 5-Fu chemotherapy were found to have a longer PFS (P=0.003, P=0.013) and OS (P=0.003, P=0.004) than patients treated with non-EPI/5-Fu-based regimens, respectively. Conclusions: Our findings confirmed the poor prognosis of high PKM2 expression in breast cancer patients and revealed the predictive value of high PKM2 in the therapeutic response to EPI and 5-Fu. Moreover, our results provide the guidance of individual treatment for breast cancer patients who are foreboded a poor prognosis by the presence of high PKM2 status.
引用
收藏
页码:1130 / 1139
页数:10
相关论文
共 50 条
  • [21] Expression of the breast cancer resistance protein and 5-fluorouracil resistance in clinical breast cancer tissue specimens
    Wang, Min
    Wang, Xianming
    Yuan, Jianhui
    Guo, Liangfeng
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (05) : 853 - 857
  • [22] Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
    Zhu, Susi
    Guo, Yeye
    Zhang, Xu
    Liu, Hong
    Yin, Mingzhu
    Chen, Xiang
    Peng, Cong
    CANCER LETTERS, 2021, 503 : 240 - 248
  • [23] ADVANCED BREAST-CANCER - A RANDOMIZED STUDY OF DIFFERENT DOSES OF EPIRUBICIN ASSOCIATED WITH FIXED DOSES OF CYCLOPHOSPHAMIDE AND 5-FLUOROURACIL
    RICCARDI, A
    GIORDANO, M
    BRUGNATELLI, S
    UCCI, G
    DANOVA, M
    MORA, O
    FAVA, S
    ASCARI, E
    ONCOLOGY REPORTS, 1995, 2 (04) : 577 - 582
  • [24] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Mozaffari, Fariba
    Lindemalm, Christina
    Choudhury, Aniruddha
    Granstam-Bjorneklett, Helena
    Lekander, Mats
    Nilsson, Bo
    Ojutkangas, Marja-Leena
    Osterborg, Anders
    Bergkvist, Leif
    Mellstedt, Hakan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 111 - 120
  • [25] Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays
    Shimizu, D
    Ishikawa, T
    Ichikawa, Y
    Togo, S
    Hayasizaki, Y
    Okazaki, Y
    Danenberg, PV
    Shimada, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 27 (02) : 371 - 376
  • [26] A retrospective study on TS mRNA expression and prediction of the effects; of adjuvant oral 5-fluorouracil in breast cancer
    Aki, Fuminori
    Bando, Yoshimi
    Takahashi, Tetsuyuki
    Uehara, Hisanori
    Numoto, Satoshi
    Ito, Sueyoshi
    Sasa, Mitsunori
    Izumi, Keisuke
    ONCOLOGY LETTERS, 2010, 1 (06) : 981 - 987
  • [27] Methionine oxidation activates pyruvate kinase M2 to promote pancreatic cancer metastasis
    He, Dan
    Feng, Huijin
    Sundberg, Belen
    Yang, Jiaxing
    Powers, Justin
    Christian, Alec H.
    Wilkinson, John E.
    Monnin, Cian
    Avizonis, Daina
    Thomas, Craig J.
    Friedman, Richard A.
    Kluger, Michael D.
    Hollingsworth, Michael A.
    Grandgenett, Paul M.
    Klute, Kelsey A.
    Toste, F. Dean
    Chang, Christopher J.
    Chio, Iok In Christine
    MOLECULAR CELL, 2022, 82 (16) : 3045 - +
  • [28] Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer
    Kitagawa, K.
    Kawada, K.
    Morita, S.
    Inada, M.
    Mitsuma, A.
    Sawaki, M.
    Iino, S.
    Inden, Y.
    Murohara, T.
    Imai, T.
    Ando, Y.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 743 - 747
  • [29] Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway
    Zhu, Qiang
    Hong, Baofa
    Zhang, Lei
    Wang, Jing
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S616 - S621
  • [30] Knockdown of EpCAM Enhances the Chemosensitivity of Breast Cancer Cells to 5-fluorouracil by Downregulating the Antiapoptotic Factor Bcl-2
    Gao, Jiujiao
    Yan, Qiu
    Liu, Shuai
    Yang, Xuesong
    PLOS ONE, 2014, 9 (07):